Literature DB >> 28930882

Reproducibility of Bruch Membrane Opening-Minimum Rim Width Measurements With Spectral Domain Optical Coherence Tomography.

Keunheung Park1, Jinmi Kim, Jiwoong Lee.   

Abstract

PURPOSE: To evaluate the reproducibility of Bruch membrane opening-minimum rim width (BMO-MRW) measurements obtained with Spectralis optical coherence tomography (OCT) in normal and glaucoma subjects.
MATERIALS AND METHODS: In total, 123 eyes from 123 subjects (65 healthy, 58 glaucoma subjects) were included. BMO-MRW measurements were repeated 3 times during the same visit using Spectralis OCT. The BMO points and internal limiting membrane were identified with automated software and corrected manually when necessary. The intravisit repeatability, coefficient of variation (CV), and intraclass correlation coefficient were analyzed for each sector and global BMO-MRW. The Spearman rank correlation coefficient was used to estimate correlations between CV and multiple variables. Multiple linear regression analysis was used to identify significant associations.
RESULTS: The intravisit repeatability ranged from 2.97 μm (global) to 10.25 μm (inferotemporal sector) in healthy subjects and from 3.31 μm (global) to 12.09 μm (inferonasal sector) in glaucoma subjects. The CVs ranged from 1.17% (global) to 3.56% (inferotemporal sector) in healthy subjects and from 2.57% (global) to 6.46% (superotemporal and inferotemporal sector) in glaucoma subjects. Intraclass correlation coefficients ranged from 0.974 (superotemporal sector) to 0.997 (nasal sector) in normal subjects and from 0.988 (temporal sector) to 0.997 (global and nasal sector) in glaucoma subjects. Multiple regression analysis showed that the CV in global BMO-MRW measurements was inversely associated with global BMO-MRW and visual field mean deviation (P=0.001 and 0.002, respectively).
CONCLUSIONS: The Spectralis SD-OCT showed excellent reproducibility in BMO-MRW measurements in both normal and glaucoma subjects. The measurements variability was worse in more advanced glaucoma.

Entities:  

Mesh:

Year:  2017        PMID: 28930882     DOI: 10.1097/IJG.0000000000000787

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  5 in total

1.  Macular Ganglion Cell and Inner Plexiform Layer Thickness Is More Strongly Associated With Visual Function in Multiple Sclerosis Than Bruch Membrane Opening-Minimum Rim Width or Peripapillary Retinal Nerve Fiber Layer Thicknesses.

Authors:  James Nguyen; Alissa Rothman; Natalia Gonzalez; Ama Avornu; Esther Ogbuokiri; Laura J Balcer; Steven L Galetta; Elliot M Frohman; Teresa Frohman; Ciprian Crainiceanu; Peter A Calabresi; Shiv Saidha
Journal:  J Neuroophthalmol       Date:  2019-12       Impact factor: 3.042

2.  Optic Nerve Head Morphological Changes Over 12 Hours in Seated and Head-Down Tilt Postures.

Authors:  Laura P Pardon; Han Cheng; Pratik Chettry; Nimesh B Patel
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-11-02       Impact factor: 4.799

3.  Reproducibility of Neuroretinal Rim Measurements Obtained from High-Density Spectral Domain Optical Coherence Tomography Volume Scans.

Authors:  Janice Kim; Clara J Men; Kitiya Ratanawongphaibul; Georgia Papadogeorgou; Edem Tsikata; Geulah S Ben-David; Hussein Antar; Linda Yi-Chieh Poon; Madeline Freeman; Elli A Park; Maria A Guzman Aparicio; Johannes F de Boer; Teresa C Chen
Journal:  Clin Ophthalmol       Date:  2022-08-13

Review 4.  Utility of combining spectral domain optical coherence tomography structural parameters for the diagnosis of early Glaucoma: a mini-review.

Authors:  Jean-Claude Mwanza; Joshua L Warren; Donald L Budenz
Journal:  Eye Vis (Lond)       Date:  2018-04-15

5.  Artifact Rates for 2D Retinal Nerve Fiber Layer Thickness Versus 3D Neuroretinal Rim Thickness Using Spectral-Domain Optical Coherence Tomography.

Authors:  Elli A Park; Edem Tsikata; Jenny Jyoung Lee; Eric Shieh; Boy Braaf; Benjamin J Vakoc; Brett E Bouma; Johannes F de Boer; Teresa C Chen
Journal:  Transl Vis Sci Technol       Date:  2020-09-10       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.